Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.26
Lucie Urbanová, Martina Sebalo Vňuková, Martin Anders, Radek Ptáček, Jitka Bušková
Sleep hygiene is essential for the prevention of somatic and mental disorders, including the prevention of sleep disorders. However, it does not typically address individual differences. The aim of this review is threefold: first, to outline the empirical evidence for particular components of sleep hygiene rules; second, to indicate the importance of individualized sleep hygiene application with regard to the varying degree of validity of sleep hygiene rules in the population; third, to highlight a new field of sleep hygiene, namely light hygiene. PubMed and Google Scholar were used to identify studies that were published between 2007 and 2022. A search was conducted for studies related to sleeping rules topics: sleep regularity, regular exercise, alcohol, caffeine, napping, relaxation and meditation, food intake and light exposure. In applying these sleep hygiene principles, it is essential to pay attention to individual variables such as age, genetic predisposition, health status, and substance (caffeine, alcohol) possible dependence.
{"title":"The Updating and Individualizing of Sleep Hygiene Rules for Non-clinical Adult Populations.","authors":"Lucie Urbanová, Martina Sebalo Vňuková, Martin Anders, Radek Ptáček, Jitka Bušková","doi":"10.14712/23362936.2023.26","DOIUrl":"https://doi.org/10.14712/23362936.2023.26","url":null,"abstract":"<p><p>Sleep hygiene is essential for the prevention of somatic and mental disorders, including the prevention of sleep disorders. However, it does not typically address individual differences. The aim of this review is threefold: first, to outline the empirical evidence for particular components of sleep hygiene rules; second, to indicate the importance of individualized sleep hygiene application with regard to the varying degree of validity of sleep hygiene rules in the population; third, to highlight a new field of sleep hygiene, namely light hygiene. PubMed and Google Scholar were used to identify studies that were published between 2007 and 2022. A search was conducted for studies related to sleeping rules topics: sleep regularity, regular exercise, alcohol, caffeine, napping, relaxation and meditation, food intake and light exposure. In applying these sleep hygiene principles, it is essential to pay attention to individual variables such as age, genetic predisposition, health status, and substance (caffeine, alcohol) possible dependence.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"329-343"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.10
Serdar Şenol, Mustafa Kuşak
Although there is extensive debate for the best treatment strategies, limited studies, which reflect the effects of postoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on mortality and hospital stay after elective gastrointestinal oncologic procedures were published. In order to contribute to the existing literature, a single-center, retrospective, cross-sectional study, including 301 patients who underwent elective gastrointestinal oncological procedures was planned. Patients' data on sex, age, diagnosis, types of procedures, hospital stay, mortality, and SARS-CoV-2 preoperative screening tests were recorded. Four of them were postponed due to positive preoperative screening for SARS-CoV-2. 395 procedures were performed due to cancer originating from colon (105), rectum (91), stomach (74), periampullar region (16), distal pancreas (4), esophagus (3), retroperitoneum (2), ovary (2), endometrium (1), spleen (1) and small bowel (2). Laparoscopy was the approach of choice for 44 patients (14.7% vs. 85.3%). In the postoperative period, two patients were infected with SARS-CoV-2 and one of them died in the intensive care unit (n=1/2, 50% mortality). Two patients died due to surgical complications unrelated to SARS-CoV-2 (n=2/299, 0.67% mortality) (p<0.01). The mean hospital stay was longer in patients with SARS-CoV-2 infection (21.5 ± 9.1 - 8.2 ± 5.2 days, respectively, p<0.01). 298 patients were safely discharged (99%). During the pandemic elective gastrointestinal oncologic procedures may be safely performed; however, preoperative testing, precautions to minimize contamination should be performed strictly to reduce in-hospital infection rates, since the mortality rate due to SARS-CoV-2 in this setting is particularly high and hospital stay is also significantly increased.
尽管对于最佳治疗策略存在广泛的争论,但反映术后严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染对选择性胃肠道肿瘤手术后死亡率和住院时间影响的有限研究已发表。为了对现有文献做出贡献,我们计划进行一项单中心、回顾性、横断面研究,包括301例接受选择性胃肠道肿瘤手术的患者。记录患者的性别、年龄、诊断、手术类型、住院时间、死亡率和SARS-CoV-2术前筛查试验等数据。其中4人因术前SARS-CoV-2筛查阳性而推迟。395例因结肠癌(105例)、直肠(91例)、胃(74例)、壶腹周围(16例)、胰腺远端(4例)、食道(3例)、腹膜后(2例)、卵巢(2例)、子宫内膜(1例)、脾脏(1例)和小肠(2例)而行手术。44例患者选择腹腔镜手术(14.7%对85.3%)。术后2例患者感染SARS-CoV-2,其中1例死亡于重症监护病房(n=1/2,死亡率50%)。2例患者死于与SARS-CoV-2无关的手术并发症(n=2/299,死亡率0.67%)(p<0.01)。SARS-CoV-2感染患者的平均住院时间更长(分别为21.5±9.1 ~ 8.2±5.2 d, p < 0.01)。298例患者安全出院(99%)。在大流行期间,可安全地进行选择性胃肠道肿瘤手术;但是,由于在这种情况下SARS-CoV-2的死亡率特别高,住院时间也显着增加,因此应严格执行术前检测和尽量减少污染的预防措施,以降低院内感染率。
{"title":"The Effects of Nasocomial SARS-CoV-2 Infection after Elective Gastrointestinal Oncologic Procedures: Single Center 30-day Follow-up Results.","authors":"Serdar Şenol, Mustafa Kuşak","doi":"10.14712/23362936.2023.10","DOIUrl":"https://doi.org/10.14712/23362936.2023.10","url":null,"abstract":"<p><p>Although there is extensive debate for the best treatment strategies, limited studies, which reflect the effects of postoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on mortality and hospital stay after elective gastrointestinal oncologic procedures were published. In order to contribute to the existing literature, a single-center, retrospective, cross-sectional study, including 301 patients who underwent elective gastrointestinal oncological procedures was planned. Patients' data on sex, age, diagnosis, types of procedures, hospital stay, mortality, and SARS-CoV-2 preoperative screening tests were recorded. Four of them were postponed due to positive preoperative screening for SARS-CoV-2. 395 procedures were performed due to cancer originating from colon (105), rectum (91), stomach (74), periampullar region (16), distal pancreas (4), esophagus (3), retroperitoneum (2), ovary (2), endometrium (1), spleen (1) and small bowel (2). Laparoscopy was the approach of choice for 44 patients (14.7% vs. 85.3%). In the postoperative period, two patients were infected with SARS-CoV-2 and one of them died in the intensive care unit (n=1/2, 50% mortality). Two patients died due to surgical complications unrelated to SARS-CoV-2 (n=2/299, 0.67% mortality) (p<0.01). The mean hospital stay was longer in patients with SARS-CoV-2 infection (21.5 ± 9.1 - 8.2 ± 5.2 days, respectively, p<0.01). 298 patients were safely discharged (99%). During the pandemic elective gastrointestinal oncologic procedures may be safely performed; however, preoperative testing, precautions to minimize contamination should be performed strictly to reduce in-hospital infection rates, since the mortality rate due to SARS-CoV-2 in this setting is particularly high and hospital stay is also significantly increased.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"143-150"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.18
Jan Moravec, Martin Müller, Petr Turek, Michal Moravec, Tomáš Nejtek, Roman Zazula
The use of convalescent plasma (CP) appeared to be a promising, easily available and safe way of treatment of severe COVID-19 at the onset of the pandemic in early 2020. Conducted in 2020 and 2021, our study of 52 severely to critically ill COVID-19 patients who received CP plasma as a treatment and of 97 controls found no difference in 30-day or 90-day mortality rates. A significant viral load drop in most patients (4.7 log10 [p<0.001] copies/ml) was observed following CP administration. Retrospective analysis of selected inflammatory markers and immunoglobulins showed higher C-reactive protein levels among the study group, and their decrease on Day 7.
{"title":"Effect of Convalescent Plasma Therapy on Mortality and Viral Load in Severely Ill Patients with COVID-19.","authors":"Jan Moravec, Martin Müller, Petr Turek, Michal Moravec, Tomáš Nejtek, Roman Zazula","doi":"10.14712/23362936.2023.18","DOIUrl":"https://doi.org/10.14712/23362936.2023.18","url":null,"abstract":"<p><p>The use of convalescent plasma (CP) appeared to be a promising, easily available and safe way of treatment of severe COVID-19 at the onset of the pandemic in early 2020. Conducted in 2020 and 2021, our study of 52 severely to critically ill COVID-19 patients who received CP plasma as a treatment and of 97 controls found no difference in 30-day or 90-day mortality rates. A significant viral load drop in most patients (4.7 log10 [p<0.001] copies/ml) was observed following CP administration. Retrospective analysis of selected inflammatory markers and immunoglobulins showed higher C-reactive protein levels among the study group, and their decrease on Day 7.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"230-241"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.19
Viktor V Semenov, Jizzo R Bosdriesz, Olexandr Kuryata
Patients with chronic kidney disease (CKD) have high cardiovascular risk (CVR), which is often underestimated by conventional tools. The coronary artery calcium score (CACS) significantly improves CVR stratification by conventional tools, but it is often not available in low-resources settings. Aldosterone may be a cheaper alternative to CACS for CVR assessment in CKD patients. The aim was to assess the ability of serum aldosterone level to predict CACS in patients with CKD in comparison to standard predictors. This single-center study included 57 patients aged 40 to 67 years with CKD (estimated glomerular filtration rate [eGFR] ≥45 ml/min) and arterial hypertension. Serum aldosterone, sex, age, body mass index, blood pressure, total cholesterol, eGFR, and proteinuria were used for prediction of CACS>0 Agatston units (AU) and CACS>100 AU. The area under the curve (AUC) with 95% confidence intervals (CI) and the mean Brier scores were examined for predictors of CACS. Aldosterone predicted a CACS>100 AU (AUC = 0.72, 95% CI: 0.56-0.88), but not a CACS>0 AU. Age predicted a CACS>100 AU (AUC = 0.80, 95% CI: 0.67-0.93) and a CACS>0 AU (AUC = 0.75, 95% CI: 0.62-0.89). The addition of aldosterone to age for prediction of a CACS>100 AU improved the mean Brier score, compared to the model with age alone, from 0.16 to 0.14, but not the AUC (0.83, 95% CI: 0.70-0.95). Aldosterone was a significant predictor of a CACS>100 AU in patients with CKD, but aldosterone was not a better predictor than age alone.
{"title":"The Predictive Value of Serum Aldosterone Level for Coronary Artery Calcium Score in Patients with Chronic Kidney Disease: A Single-center Study.","authors":"Viktor V Semenov, Jizzo R Bosdriesz, Olexandr Kuryata","doi":"10.14712/23362936.2023.19","DOIUrl":"https://doi.org/10.14712/23362936.2023.19","url":null,"abstract":"<p><p>Patients with chronic kidney disease (CKD) have high cardiovascular risk (CVR), which is often underestimated by conventional tools. The coronary artery calcium score (CACS) significantly improves CVR stratification by conventional tools, but it is often not available in low-resources settings. Aldosterone may be a cheaper alternative to CACS for CVR assessment in CKD patients. The aim was to assess the ability of serum aldosterone level to predict CACS in patients with CKD in comparison to standard predictors. This single-center study included 57 patients aged 40 to 67 years with CKD (estimated glomerular filtration rate [eGFR] ≥45 ml/min) and arterial hypertension. Serum aldosterone, sex, age, body mass index, blood pressure, total cholesterol, eGFR, and proteinuria were used for prediction of CACS>0 Agatston units (AU) and CACS>100 AU. The area under the curve (AUC) with 95% confidence intervals (CI) and the mean Brier scores were examined for predictors of CACS. Aldosterone predicted a CACS>100 AU (AUC = 0.72, 95% CI: 0.56-0.88), but not a CACS>0 AU. Age predicted a CACS>100 AU (AUC = 0.80, 95% CI: 0.67-0.93) and a CACS>0 AU (AUC = 0.75, 95% CI: 0.62-0.89). The addition of aldosterone to age for prediction of a CACS>100 AU improved the mean Brier score, compared to the model with age alone, from 0.16 to 0.14, but not the AUC (0.83, 95% CI: 0.70-0.95). Aldosterone was a significant predictor of a CACS>100 AU in patients with CKD, but aldosterone was not a better predictor than age alone.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"242-254"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.32
Kwang Sheng Ng, Mohammad Hudzaifah-Nordin, Sathyapriya Tamilarsan Sarah, Wan Hitam Wan-Hazabbah, Abd Halim Sanihah
To evaluate the retinal nerve fibre layer (RNFL) thickness and choroidal thickness (CT) in Parkinson disease (PD) patients. A comparative cross-sectional, hospital-based study. 39 PD and 39 controls were recruited, who were gender and age matched. Subjects that fulfilled the inclusion criteria underwent optical coherence tomography for evaluation of RNFL thickness and choroidal thickness (CT). There was significant reduction of RNFL thickness in average (adjusted mean 88.87 µm vs. 94.82 µm, P=0.001), superior (adjusted mean 110.08 µm vs. 119.10 µm, P=0.002) and temporal (adjusted mean 63.77 µm vs. 70.36 µm, P=0.004) in PD compared to controls. The central subfoveal CT was significantly thinner in PD compared to controls (adjusted mean 271.13 µm vs. 285.10 µm, P=0.003). In PD group, there was significant weak negative correlation between the duration of PD with average RNFL thickness (r=-0.354, P=0.027), moderate negative correlation between the duration of PD with central subfoveal CT (r=-0.493, P=0.001), and weak negative correlation between the stage of PD with central subfoveal CT (r=-0.380, P=0.017). PD group had significant thinner average, superior and temporal RNFL thickness and CT compared to controls.
{"title":"Evaluation of Retinal Nerve Fibre Layer Thickness and Choroidal Thickness in Parkinson Disease Patients.","authors":"Kwang Sheng Ng, Mohammad Hudzaifah-Nordin, Sathyapriya Tamilarsan Sarah, Wan Hitam Wan-Hazabbah, Abd Halim Sanihah","doi":"10.14712/23362936.2023.32","DOIUrl":"https://doi.org/10.14712/23362936.2023.32","url":null,"abstract":"<p><p>To evaluate the retinal nerve fibre layer (RNFL) thickness and choroidal thickness (CT) in Parkinson disease (PD) patients. A comparative cross-sectional, hospital-based study. 39 PD and 39 controls were recruited, who were gender and age matched. Subjects that fulfilled the inclusion criteria underwent optical coherence tomography for evaluation of RNFL thickness and choroidal thickness (CT). There was significant reduction of RNFL thickness in average (adjusted mean 88.87 µm vs. 94.82 µm, P=0.001), superior (adjusted mean 110.08 µm vs. 119.10 µm, P=0.002) and temporal (adjusted mean 63.77 µm vs. 70.36 µm, P=0.004) in PD compared to controls. The central subfoveal CT was significantly thinner in PD compared to controls (adjusted mean 271.13 µm vs. 285.10 µm, P=0.003). In PD group, there was significant weak negative correlation between the duration of PD with average RNFL thickness (r=-0.354, P=0.027), moderate negative correlation between the duration of PD with central subfoveal CT (r=-0.493, P=0.001), and weak negative correlation between the stage of PD with central subfoveal CT (r=-0.380, P=0.017). PD group had significant thinner average, superior and temporal RNFL thickness and CT compared to controls.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"421-434"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.30
Ricardo Enrique Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto Alejandro Diez, Guido Giunti
The COVID-19 pandemic generated a great impact on health systems. We compared evolution, polypharmacy, and potential drug-drug interactions (P-DDIs) in COVID-19 and non-COVID-19 hospitalizations during first wave of pandemic. Prescriptions for hospitalized patients ≥ 18 years (COVID-19 and non-COVID-19 rooms) between April and September 2020 were included. The computerized medical decision support system SIMDA and the physician order entry system Hdc.DrApp.la were used. Patients in COVID-19 rooms were divided into detectable and non-detectable, according to real-time reverse transcription polymerase chain reaction (RT-PCR). Number of drugs, prescribed on day 1, after day 1, and total; polypharmacy, excessive polypharmacy, and P-DDIs were compared. 1,623 admissions were evaluated: 881 COVID-19, 538 detectable and 343 non-detectable, and 742 non-COVID-19. Mortality was 15% in COVID-19 and 13% in non-COVID-19 (RR [non-COVID-19 vs. COVID-19]: 0.84 [95% CI] [0.66-1.07]). In COVID-19, mortality was 19% in detectable and 9% in non-detectable (RR: 2.07 [1.42-3.00]). Average number of drugs was 4.54/patient (SD ± 3.06) in COVID-19 and 5.92/patient (±3.24) in non-COVID-19 (p<0.001) on day 1 and 5.57/patient (±3.93) in COVID-19 and 9.17/patient (±5.27) in non-COVID-19 (p<0.001) throughout the hospitalization. 45% received polypharmacy in COVID-19 and 62% in non-COVID-19 (RR: 1.38 [1.25-1.51]) and excessive polypharmacy 7% in COVID-19 and 14% in non-COVID-19 (RR: 2.09 [1.54-2.83]). The frequency of total P-DDIs was 0.31/patient (±0.67) in COVID-19 and 0.40/patient (±0.94) in non-COVID-19 (p=0.022). Hospitalizations in the COVID-19 setting are associated with less use of drugs, less polypharmacy and less P-DDIs. Detectable patients had higher mortality.
{"title":"Polypharmacy and Drug Interactions in the COVID-19 Pandemic.","authors":"Ricardo Enrique Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto Alejandro Diez, Guido Giunti","doi":"10.14712/23362936.2023.30","DOIUrl":"https://doi.org/10.14712/23362936.2023.30","url":null,"abstract":"<p><p>The COVID-19 pandemic generated a great impact on health systems. We compared evolution, polypharmacy, and potential drug-drug interactions (P-DDIs) in COVID-19 and non-COVID-19 hospitalizations during first wave of pandemic. Prescriptions for hospitalized patients ≥ 18 years (COVID-19 and non-COVID-19 rooms) between April and September 2020 were included. The computerized medical decision support system SIMDA and the physician order entry system Hdc.DrApp.la were used. Patients in COVID-19 rooms were divided into detectable and non-detectable, according to real-time reverse transcription polymerase chain reaction (RT-PCR). Number of drugs, prescribed on day 1, after day 1, and total; polypharmacy, excessive polypharmacy, and P-DDIs were compared. 1,623 admissions were evaluated: 881 COVID-19, 538 detectable and 343 non-detectable, and 742 non-COVID-19. Mortality was 15% in COVID-19 and 13% in non-COVID-19 (RR [non-COVID-19 vs. COVID-19]: 0.84 [95% CI] [0.66-1.07]). In COVID-19, mortality was 19% in detectable and 9% in non-detectable (RR: 2.07 [1.42-3.00]). Average number of drugs was 4.54/patient (SD ± 3.06) in COVID-19 and 5.92/patient (±3.24) in non-COVID-19 (p<0.001) on day 1 and 5.57/patient (±3.93) in COVID-19 and 9.17/patient (±5.27) in non-COVID-19 (p<0.001) throughout the hospitalization. 45% received polypharmacy in COVID-19 and 62% in non-COVID-19 (RR: 1.38 [1.25-1.51]) and excessive polypharmacy 7% in COVID-19 and 14% in non-COVID-19 (RR: 2.09 [1.54-2.83]). The frequency of total P-DDIs was 0.31/patient (±0.67) in COVID-19 and 0.40/patient (±0.94) in non-COVID-19 (p=0.022). Hospitalizations in the COVID-19 setting are associated with less use of drugs, less polypharmacy and less P-DDIs. Detectable patients had higher mortality.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"392-412"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.7
Amitabha Ray, Kristen A K Winter, Dayalu S L Naik, Chuku Okorie
Infection with the SARS-CoV-2 virus (COVID-19 disease) can cause a wide range of clinical situations - from an asymptomatic state to fatal outcomes. In cases of serious clinical manifestations, the underlying mechanisms involve a number of immune cells and stromal cells as well as their products such as pro-inflammatory interleukin-6 and tumour necrosis factor-alpha that ultimately cause the cytokine storm. The situation of overproduction of pro-inflammatory cytokines is somewhat similar to, though in a mild form, health conditions in obesity and related metabolic disorders like type-2 diabetes, which are also considered important risk factors for severe illness in COVID-19. Interestingly, neutrophils perhaps play a significant role in this pathogenesis. On the other hand, it is thought that COVID-19-related critical illness is associated with pathological hyperactivity of the complement system and coagulopathy. Although the precise molecular interactions between the complement and coagulation systems are not clear, we observe an intimate cross-talk between these two systems in critically ill COVID-19 patients. It is believed that both of these biological systems are connected with the cytokine storm in severe COVID-19 disease and actively participate in this vicious cycle. In order to hinder the pathological progression of COVID-19, a number of anticoagulation agents and complement inhibitors have been used with varying success. Among these drugs, low molecular weight heparin enoxaparin, factor Xa inhibitor apixaban, and complement C5 inhibitor eculizumab have been commonly used in patients with COVID-19. Our overall experience might help us in the future to tackle any such conditions.
{"title":"Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection.","authors":"Amitabha Ray, Kristen A K Winter, Dayalu S L Naik, Chuku Okorie","doi":"10.14712/23362936.2023.7","DOIUrl":"https://doi.org/10.14712/23362936.2023.7","url":null,"abstract":"<p><p>Infection with the SARS-CoV-2 virus (COVID-19 disease) can cause a wide range of clinical situations - from an asymptomatic state to fatal outcomes. In cases of serious clinical manifestations, the underlying mechanisms involve a number of immune cells and stromal cells as well as their products such as pro-inflammatory interleukin-6 and tumour necrosis factor-alpha that ultimately cause the cytokine storm. The situation of overproduction of pro-inflammatory cytokines is somewhat similar to, though in a mild form, health conditions in obesity and related metabolic disorders like type-2 diabetes, which are also considered important risk factors for severe illness in COVID-19. Interestingly, neutrophils perhaps play a significant role in this pathogenesis. On the other hand, it is thought that COVID-19-related critical illness is associated with pathological hyperactivity of the complement system and coagulopathy. Although the precise molecular interactions between the complement and coagulation systems are not clear, we observe an intimate cross-talk between these two systems in critically ill COVID-19 patients. It is believed that both of these biological systems are connected with the cytokine storm in severe COVID-19 disease and actively participate in this vicious cycle. In order to hinder the pathological progression of COVID-19, a number of anticoagulation agents and complement inhibitors have been used with varying success. Among these drugs, low molecular weight heparin enoxaparin, factor Xa inhibitor apixaban, and complement C5 inhibitor eculizumab have been commonly used in patients with COVID-19. Our overall experience might help us in the future to tackle any such conditions.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"77-93"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.16
Judita Staša, Jana Gregorová, Ondřej Slanař, Martin Šíma
Targeted therapy with protein kinase inhibitors (PKIs) represents one of the important treatment options for non-small cell lung cancer (NSCLC). It has contributed to improve patients' survival and quality of life significantly. These anticancer drugs are administrated orally in flat-fixed doses despite the well-known large interpatient pharmacokinetic variability and the possible need for dose individualization. To optimize and individualize dosing of PKIs, and thereby increasing the effectiveness and safety of the treatment, therapeutic drug monitoring (TDM) is the most frequently mentioned method. Unlike other areas of medicine, TDM has been rather exceptional in oncological practise since there is a little evidence or no data for concentration-effect relationships of PKIs. Therefore, the aim of this review is to summarize the pharmacokinetic characteristics of PKIs and provide the evidence supporting the use of TDM for personalised treatment of patients with NSCLC.
{"title":"Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer.","authors":"Judita Staša, Jana Gregorová, Ondřej Slanař, Martin Šíma","doi":"10.14712/23362936.2023.16","DOIUrl":"https://doi.org/10.14712/23362936.2023.16","url":null,"abstract":"<p><p>Targeted therapy with protein kinase inhibitors (PKIs) represents one of the important treatment options for non-small cell lung cancer (NSCLC). It has contributed to improve patients' survival and quality of life significantly. These anticancer drugs are administrated orally in flat-fixed doses despite the well-known large interpatient pharmacokinetic variability and the possible need for dose individualization. To optimize and individualize dosing of PKIs, and thereby increasing the effectiveness and safety of the treatment, therapeutic drug monitoring (TDM) is the most frequently mentioned method. Unlike other areas of medicine, TDM has been rather exceptional in oncological practise since there is a little evidence or no data for concentration-effect relationships of PKIs. Therefore, the aim of this review is to summarize the pharmacokinetic characteristics of PKIs and provide the evidence supporting the use of TDM for personalised treatment of patients with NSCLC.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 3","pages":"199-215"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41156272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.28
Clóvis Lamartine de Moraes Melo Neto, Daniela Micheline Dos Santos, Marcelo Coelho Goiato
During the fabrication of a complete denture, functional impression is taken. Literature studies show that polydimethylsiloxane (condensation silicone) has not been reported by United States dental schools to perform border molding. Thus, the purpose of this article is to review the functional impression technique when border molding is performed with a laboratory condensation silicone putty.
{"title":"Complete Denture - Border Molding Technique Using a Laboratory Condensation Silicone Putty: Review.","authors":"Clóvis Lamartine de Moraes Melo Neto, Daniela Micheline Dos Santos, Marcelo Coelho Goiato","doi":"10.14712/23362936.2023.28","DOIUrl":"https://doi.org/10.14712/23362936.2023.28","url":null,"abstract":"<p><p>During the fabrication of a complete denture, functional impression is taken. Literature studies show that polydimethylsiloxane (condensation silicone) has not been reported by United States dental schools to perform border molding. Thus, the purpose of this article is to review the functional impression technique when border molding is performed with a laboratory condensation silicone putty.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 4","pages":"359-379"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14712/23362936.2023.9
Stoyan Kostov, Svetla Dineva, Yavor Kornovski, Stanislav Slavchev, Yonka Ivanova, Angel Yordanov
Detailed knowledge of the human anatomy is an integral part of every surgical procedure. The majority of surgery related complications are due to a failure to possess appropriate knowledge of human anatomy. However, surgeons pay less attention of the anatomy of the anterior abdominal wall. It is composed of nine abdominal layers, which are composed of fascias, muscles, nerves, and vessels. Many superficial and deep vessels and their anastomoses supply the anterior abdominal wall. Moreover, anatomical variations of these vessels are often presented. Intraoperative and postoperative complications associated with entry and closure of the anterior abdominal wall could compromise the best surgical procedure. Therefore, sound knowledge of the vascular anatomy of the anterior abdominal wall is fundamental and a prerequisite to having a favourable quality of patient care. The purpose of the present article is to describe and delineate the vascular anatomy and variations of the anterior abdominal wall and its application in abdominal surgery. Consequently, the most types of abdominal incisions and laparoscopic accesses will be discussed. Furthermore, the possibility of vessels injury related to different types of incisions and accesses will be outlined in detail. Morphological characteristics and distribution pattern of the vascular system of the anterior abdominal wall is illustrated by using figures either from open surgery, different types of imaging modalities or embalmed cadaveric dissections. Oblique skin incisions in the upper or lower abdomen such as McBurney, Chevron and Kocher are not the topic of the present article.
{"title":"Vascular Anatomy and Variations of the Anterior Abdominal Wall - Significance in Abdominal Surgery.","authors":"Stoyan Kostov, Svetla Dineva, Yavor Kornovski, Stanislav Slavchev, Yonka Ivanova, Angel Yordanov","doi":"10.14712/23362936.2023.9","DOIUrl":"https://doi.org/10.14712/23362936.2023.9","url":null,"abstract":"<p><p>Detailed knowledge of the human anatomy is an integral part of every surgical procedure. The majority of surgery related complications are due to a failure to possess appropriate knowledge of human anatomy. However, surgeons pay less attention of the anatomy of the anterior abdominal wall. It is composed of nine abdominal layers, which are composed of fascias, muscles, nerves, and vessels. Many superficial and deep vessels and their anastomoses supply the anterior abdominal wall. Moreover, anatomical variations of these vessels are often presented. Intraoperative and postoperative complications associated with entry and closure of the anterior abdominal wall could compromise the best surgical procedure. Therefore, sound knowledge of the vascular anatomy of the anterior abdominal wall is fundamental and a prerequisite to having a favourable quality of patient care. The purpose of the present article is to describe and delineate the vascular anatomy and variations of the anterior abdominal wall and its application in abdominal surgery. Consequently, the most types of abdominal incisions and laparoscopic accesses will be discussed. Furthermore, the possibility of vessels injury related to different types of incisions and accesses will be outlined in detail. Morphological characteristics and distribution pattern of the vascular system of the anterior abdominal wall is illustrated by using figures either from open surgery, different types of imaging modalities or embalmed cadaveric dissections. Oblique skin incisions in the upper or lower abdomen such as McBurney, Chevron and Kocher are not the topic of the present article.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":"124 2","pages":"108-142"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}